Intercept Pharma Stock Tumbles: FDA Panel Votes Against Intercept's Fatty Liver Drug, Dashing Its...

Published on 22 May 2023 on Benzinga via Yahoo Finance

Intercept Pharma Stock Tumbles: FDA Panel Votes Against Intercept's Fatty Liver Drug, Dashing Its...

FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's (NASDAQ: ICPT) Ocaliva 25 mg, also known as Obeticholic acid (OCA), don't outweigh the risks in nonalcoholic steatohepatitis (NASH) patients with stage 2 or 3 fibrosis.

Read the rest of the article

NASDAQ.ICPT price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Jefferies Group's Strategic Moves: A Deep Dive into Allstate Corp's Significant Reduction

Insights from Jefferies Group (Trades, Portfolio)'s Latest 13F Filing for Q3 2023 Warning! GuruFo...

GuruFocus.com via Yahoo Finance 14 Nov 2023

10 Best Performing Healthcare ETFs in 2023

In this piece, we will take a look at the ten best performing healthcare ETFs in 2023. If you wan...

Insider Monkey via Yahoo Finance 14 Nov 2023

Dow Tumbles 150 Points; US House Prices Rise in July - Conduit Pharmaceuticals (NASDAQ:CDT), Femasys...

U.S. stocks traded lower this morning, with the Dow Jones falling around 150 points on Tuesday. F...

Benzinga 26 Sep 2023

Intercept (ICPT) Q2 Earnings Top Estimates, Revenues Up Y/Y

Intercept Pharmaceuticals ICPT incurred a loss of 14 cents per share (from continuing operations)...

Zacks via Yahoo Finance 2 Aug 2023

Intercept (ICPT) to Restructure Operations, Cut Workforce

Intercept Pharmaceuticals, Inc. ICPT announced a restructuring program in the wake of the recent ...

Zacks via Yahoo Finance 26 Jun 2023

Intercept (ICPT) NDA for NASH Treatment Gets CRL From FDA

Intercept Pharmaceuticals, Inc. ICPT announced that the FDA issued a complete response letter (CR...

Zacks via Yahoo Finance 23 Jun 2023

Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Shift From Loss To Profit

We feel now is a pretty good time to analyse Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) busi...

Simply Wall St. via Yahoo Finance 31 May 2023

The Rising Challenge for Intercept Pharmaceuticals: Analyst Downgrade Amid Ocaliva's DILI Concerns...

Canaccord Genuity has lowered the price target for Intercept Pharmaceutical Inc (NASDAQ: ICPT) fr...

Investing.com 23 May 2023

Intercept (ICPT) NASH Treatment Fails to Get GIDAC Recommendation

Intercept Pharmaceuticals, Inc. ICPT announced that the FDA’s Gastrointestinal Drugs Advisory Com...

Zacks via Yahoo Finance 22 May 2023

Intercept Pharma Stock Tumbles: FDA Panel Votes Against Intercept's Fatty Liver Drug, Dashing Its...

FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benef...

Benzinga via Yahoo Finance 22 May 2023

News

Intercept Pharma Stock Tumbles: FDA Panel Votes Against Intercept's Fatty Liver Drug, Dashing Its...

NASDAQ.ICPT price evolution

Want to become a better investor?